Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 23;110(1):99–108. doi: 10.1111/ejh.13878

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

PMC Copyright notice

Humoral and T‐cell immune response after fourth BNT162b2 mRNA COVID‐19 vaccine. Spike specific T‐cell response was determined using IFNγ‐release assay in (n = 26) patients with CLL. Scatter plots of T‐cell response vs. anti‐SARS CoV‐2 Spike protein antibody titers (A) and anti‐SARS CoV‐2 neutralizing antibody titers (B) reveals no significant correlation between T‐cell response and neither antibodies (Peasron's product–moment R = .02, .036; F‐test p = .92, .87, respectively). (C) Boxplots show significant rise in T‐cell response after fourth vaccine (Wilcoxon p < .001). T‐cell response was significantly elevated in untreated patients (n = 14, p = .003) and BTKi‐treated patients (n = 12, p = .03)